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ABSTRAKT V ANGLICKÉM JAZYCE 
Immunotherapy of ovarian carcinoma with dendritic cells 
Anticancer immunotherapy is a therapeutical strategy aimed at elicitation                 
and maintenance of immune responses against cancer cells. In this study we have focused on 
immunotherapy of ovarian cancer, because it is one of the most common gynaecological 
tumors with poor prognosis and high mortality. Our immunotherapy protocol involves 
preparing dendritic cells (DC) from monocytes isolated from patient’s peripheral blood, 
which are subsequently pulsed with irradiated cells of established ovarian cancer cell line. 
These immature pulsed DC are maturated and subsequently      co-cultivated with autologous 
T lymphocytes. The aim of this study was to demonstrate, that DC are able to elicit specific 
immune response after addition of suitable mature agens in combination with apoptotic 
ovarian tumor cells. Our observations indicate that 24 hours are sufficient for induction of 
tumor cells apoptosis. Additionally, we have shown that DC successfully ingested most of the 
apoptotic tumor cells after 4 hours of  co-incubation. Furthermore, we have found out that 
ingestion of apoptotic cells by dendritic cells, which are stimulated with polyI:C, inhibits 
maturation of DC and consequently also production of cytokines IL-12p70, IL-6 and TNF-α. 
Whereas DC maturation rate markedly affects induction of specific immune responses, in the 
case of pulsed DC, in comparison with nonpulsed DC, was decreased ratio of IFN-γ+                   
T lymphocytes. We suppose that ingestion of apoptotic cells impaired maturation of DC 
induced by polyI:C and consequently diminished their capacity to stimulate specific               
T lymphocytes. 
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